Evidence map›Paper›PMID 31627311›Full record

ArticleBrain sciences2019

Pre- and Post-Treatment with Novel Antiepileptic Drug Oxcarbazepine Exerts Neuroprotective Effect in the Hippocampus in a Gerbil Model of Transient Global Cerebral Ischemia.

Ji Hyeon Ahn, Bich Na Shin, Joon Ha Park, Tae-Kyeong Lee, Young Eun Park, Jae-Chul Lee, Go Eun Yang, Myoung Cheol Shin, Jun Hwi Cho, Kyu Chang Lee and 2 more

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Tanshinone-IIA mediated neuroprotection by modulating neuronal pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ji Hyeon AhnDepartment of Biomedical Science, Research Institute of Bioscience and Biotechnology, Hallym University, Chuncheon, Gangwon 24252, Korea. jh-ahn@hallym.ac.kr.
Bich Na ShinDepartment of Physiology, School of Medicine, Hallym University, Chuncheon, Gangwon 24252, Korea. tlsqlsck21@nate.com.
Joon Ha ParkDepartment of Anatomy, College of Korean Medicine, Dongguk University, Gyeongju, Gyeongbuk 38066, Korea. jh-park@dongguk.ac.kr.
Tae-Kyeong LeeDepartment of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea. xorud312@naver.com.
Young Eun ParkDepartment of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea. taeparo@naver.com.
Jae-Chul LeeDepartment of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea. anajclee@kangwon.ac.kr.
Go Eun YangDepartment of Radiology, Kangwon National University Hospital, Chuncheon, Gangwon 24289, Korea. yangke@kangwon.ac.kr.
Myoung Cheol ShinDepartment of Emergency Medicine, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea. dr10126@naver.com.
Jun Hwi ChoDepartment of Emergency Medicine, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea. cjhemd@kangwon.ac.kr.
Kyu Chang LeeDepartment of Anesthesiology and Pain Medicine, Chungju Hospital, Konkuk University School of Medicine, Chungju, Chungbuk 27376, Korea. leekyu@kku.ac.kr.
Moo-Ho WonDepartment of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea. mhwon@kangwon.ac.kr.ORCID 0000-0002-7178-6501
Hyeyoung KimDepartment of Emergency Medicine, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea. hae1127@kku.ac.kr.
Kangwon National University · KRHallym University · KRDongguk University · KRKangwon National University Hospital · KRKonkuk University · KR

Funding

Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT &Future Planning NRF-2016R1D1A1B01011790Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT &Future Planning NRF-2017R1A2B4009079Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT &Future Planning NRF-2018R1D1A1B07049594
6 · The paper itself

Abstract

Oxcarbazepine, an antiepileptic drug, has been reported to modulate voltage-dependent sodium channels, and it is commonly used in epilepsy treatment. In this study, we investigated the neuroprotective effect of oxcarbazepine in the hippocampus after transient ischemia in gerbils. Gerbils randomly received oxcarbazepine 100 or 200 mg/kg before and after transient ischemia. We examined its neuroprotective effect in the cornu ammonis 1 subfield of the gerbil hippocampus at 5 days after transient ischemia by using cresyl violet staining, neuronal nuclei immunohistochemistry and Fluoro-Jade B histofluorescence staining for neuroprotection, and by using glial fibrillary protein and ionized calcium-binding adapter molecule 1 immunohistochemistry for reaction of astrocytes and microglia, respectively. Pre- and post-treatment with 200 mg/kg of oxcarbazepine, but not 100 mg/kg of oxcarbazepine, protected pyramidal neurons of the cornu ammonis 1 subfield from transient ischemic damage. In addition, pre- and post-treatment with oxcarbazepine (200 mg/kg) significantly ameliorated astrocytes and microglia activation in the ischemic cornu ammonis 1 subfield. In brief, our current results indicate that post-treatment as well as pre-treatment with 200 mg/kg of oxcarbazepine can protect neurons from ischemic insults via attenuation of the glia reaction.

Indexed as

anti-epileptic drugglial activationneuroprotectionpyramidal neuronstransient cerebral ischemia

Identifiers

PMID31627311
PMCPMC6826395
OpenAlexW2981277853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.